Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer - Concepedia

Concepedia

Publication | Open Access

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

DOI Full Paper Access

85

Citations

13

References

2008

Year

Stephanie L. Hines, Betty A. Mincey, Jeff A. Sloan, Sachdev Thomas, Elaine G. Chottiner, Charles L. Loprinzi, Mark D. Carlson, Philip J. Atherton, Muhammad Salim, Edith A. Perez

Journal of Clinical Oncology

Abstract

Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer.

References

	Year	Citations

Page 1